Findings indicated that in dogs with cutaneous MCTs, prognostication should not rely on histologic grade alone, regardless of grading system used, but should take into account results of clinical staging.
Objective -To report the outcomes associated with sentinel lymph nodes (SLNs) detection and extirpation guided by radionuclide and methylene blue injections in dogs with cutaneous and subcutaneous mast cell tumors (MCTs).Study Design -Clinical prospective cohort study. Animals -30 client-owned dogs with MCTs amenable to wide-margin excision, without evidence of distant metastasis and abnormal regional lymph nodes (RLNs).Methods -Technetium-99m and methylene blue were injected peritumorally. Dogs underwent pre-operative gamma camera scintigraphy, and an intraoperative gamma probe guided SLN extirpation. Outcomes included technical and surgical complications, number of SLNs, SLNs location respecting the expected RLN, and histopathology results.Results -SLN mapping was applied to 34 MCTs in 30 dogs without any complication.SLNs were not identified in 3/34 tumors, all with previous scar tissue. SLNs did not correspond to expected RLNs in 19/30 (63%) tumors. Histological examination confirmed an early or overt metastasis in 32/57 (56%) SLNs extirpated.Conclusion -SLN mapping and biopsy with radionuclide and injection of methylene blue was associated with low morbidity and allowed detection of SLNs in dogs with MCT at first presentation without scar tissue.Clinical significance -Incorporation of SLN mapping and extirpation allows for a personalized staging approach in dogs with MCT. The presence of scar tissue in dogs with recurrent tumors seems to be a limitation for SLN mapping with this technique.
Metastasis to regional lymph nodes (RLNs) in dogs with cutaneous mast cell tumour (cMCT) has been correlated with shortened survival time and higher risk of spread to distant sites. In the present study, extirpation of non-palpable or normal-sized RLNs was included in the surgical management of cMCT in dogs. Correlations between histological nodal status (HN0-3) and tumour variables were analysed. Ninety-three dogs with single cMCT without distant metastasis that underwent wide surgical excision of the primary tumour and extirpation of non-palpable or normal-sized RLN were included. The association between HN (HN0 vs HN > 0; HN0-1 vs HN2-3) and tumour variables (site, longest diameter, ulceration, 3-tier and 2-tier histological grades) was analysed by a generalized linear model with multinomial error. Then, 33 (35.5%) RLNs were HN0, 14 (15%) were HN1, 26 (28%) were HN2 and 20 (21.5%) were HN3. The presence of positive (HN > 0) RLN was significantly associated with cMCT larger than 3 cm. No other association was statistically significant. Non-palpable/normal-sized RLN in dogs with cMCT can harbour histologically detectable metastatic disease in nearly half of the cases. Extirpation of the RLN should always perfomed to obtain a correct staging of the disease, even in the absence of clinical suspicion of metastasis. Further studies should evaluate the possible therapeutical effect of the tumour burden reduction obtained by exrtipartion of a positive RLN.
IHC must always be performed to confirm FIP. If this is not possible, when histopathology is controversial, elevated AGP concentrations may support the diagnosis of FIP.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.